SEC Comment Letter for AXIM BIOTECHNOLOGIES, INC. (AXIM) (CIK 0001514946) (AXIM) — Jul 29, 2022
AXIM BIOTECHNOLOGIES, INC. (AXIM) (CIK 0001514946)
Date: July 29, 2022 · CIK: 0001514946 · Accession: 0000000000-22-008008
AI Filing Summary & Sentiment
File numbers found in text: 333-266305
Letter
United States securities and exchange commission logo July 29, 2022 John W. Huemoeller President AXIM Biotechnologies, Inc. 6191 Cornerstone Court, E. Suite 114 San Diego, CA 92121 Re:AXIM Biotechnologies, Inc. Registration Statement on Form S-1 Filed July 25, 2022 File No. 333-266305 Dear Mr. Huemoeller: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Christopher L. Tinen, Esq.
Show Raw Text
United States securities and exchange commission logo
July 29, 2022
John W. Huemoeller
President
AXIM Biotechnologies, Inc.
6191 Cornerstone Court, E. Suite 114
San Diego, CA 92121
Re:AXIM Biotechnologies, Inc.
Registration Statement on Form S-1
Filed July 25, 2022
File No. 333-266305
Dear Mr. Huemoeller:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Christopher L. Tinen, Esq.